A multicenter, open-label, randomized, study to compare the efficacy and safety of indinavir 800 mg b.i.d. [twice daily] plus ritonavir 100 mg b.i.d. plus two NRTIs [nucleoside reverse transcriptase inhibitor] vs. nelfinavir 1250 mg b.i.d. plus two NRTIs in HIV-1 seropositive patients who have failed or are intolerant to an NNRTI [non-nucleoside reverse transcriptase inhibitor] containing regimen

Trial Profile

A multicenter, open-label, randomized, study to compare the efficacy and safety of indinavir 800 mg b.i.d. [twice daily] plus ritonavir 100 mg b.i.d. plus two NRTIs [nucleoside reverse transcriptase inhibitor] vs. nelfinavir 1250 mg b.i.d. plus two NRTIs in HIV-1 seropositive patients who have failed or are intolerant to an NNRTI [non-nucleoside reverse transcriptase inhibitor] containing regimen

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Feb 2017

At a glance

  • Drugs Indinavir; Nelfinavir; Nucleoside reverse transcriptase inhibitors; Ritonavir
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Sponsors Merck & Co
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 18 Oct 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top